A decade later, GMP problems cost Schering-Plough another $165 million
This article was originally published in The Gold Sheet
Manufacturing problems at four facilities in the late 1990s continue to haunt Schering-Plough. The company paid $165 million last month to settle a related shareholder class action. The shareholders alleged that Schering had delayed disclosure of the severity of the GMP issues and the risk that FDA would respond by holding up approval of its allergy drug Clarinex, a successor to Claritin. FDA delayed the launch by a year ("The Gold Sheet," June 2002)
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.